文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症多药耐药相关分子机制的研究进展

Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers.

作者信息

Zhang Lei, Ye Biwei, Chen Zhuo, Chen Zhe-Sheng

机构信息

State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

Acta Pharm Sin B. 2023 Mar;13(3):982-997. doi: 10.1016/j.apsb.2022.10.002. Epub 2022 Oct 7.


DOI:10.1016/j.apsb.2022.10.002
PMID:36970215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10031261/
Abstract

Chemotherapy is one of the important methods to treat cancer, and the emergence of multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy. Almost all anti-tumor drugs develop drug resistance over a period of time of application in cancer patients, reducing their effects on killing cancer cells. Chemoresistance can lead to a rapid recurrence of cancers and ultimately patient death. MDR may be induced by multiple mechanisms, which are associated with a complex process of multiple genes, factors, pathways, and multiple steps, and today the MDR-associated mechanisms are largely unknown. In this paper, from the aspects of protein-protein interactions, alternative splicing (AS) in pre-mRNA, non-coding RNA (ncRNA) mediation, genome mutations, variance in cell functions, and influence from the tumor microenvironment, we summarize the molecular mechanisms associated with MDR in cancers. In the end, prospects for the exploration of antitumor drugs that can reverse MDR are briefly discussed from the angle of drug systems with improved targeting properties, biocompatibility, availability, and other advantages.

摘要

化疗是治疗癌症的重要方法之一,而多药耐药性(MDR)的出现是癌症化疗失败的一个主要原因。几乎所有抗肿瘤药物在癌症患者应用一段时间后都会产生耐药性,降低其对癌细胞的杀伤作用。化疗耐药可导致癌症迅速复发并最终导致患者死亡。MDR可能由多种机制诱导,这些机制与多个基因、因子、途径和多个步骤的复杂过程相关,而目前与MDR相关的机制在很大程度上尚不清楚。本文从蛋白质-蛋白质相互作用、前体mRNA中的可变剪接(AS)、非编码RNA(ncRNA)介导、基因组突变、细胞功能变化以及肿瘤微环境的影响等方面,总结了癌症中与MDR相关的分子机制。最后,从具有改善的靶向性、生物相容性、可及性等优点的药物系统角度,简要讨论了探索能够逆转MDR的抗肿瘤药物的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/473e65d85fef/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/fadcbf072fa5/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/745763d34be1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/4d7e36627244/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/6dcb3f27c584/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/f08c0d40ec26/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/473e65d85fef/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/fadcbf072fa5/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/745763d34be1/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/4d7e36627244/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/6dcb3f27c584/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/f08c0d40ec26/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5dd/10031261/473e65d85fef/gr5.jpg

相似文献

[1]
Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers.

Acta Pharm Sin B. 2023-3

[2]
Therapeutic strategies to overcome taxane resistance in cancer.

Drug Resist Updat. 2021-3

[3]
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.

Drug Resist Updat. 2020-5

[4]
Multidrug resistance: molecular mechanisms and clinical relevance.

Cancer Chemother Pharmacol. 1997

[5]
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.

Drug Resist Updat. 2020-12

[6]
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

Curr Med Chem. 2006

[7]
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.

Expert Opin Drug Metab Toxicol. 2021-3

[8]
The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

Curr Drug Targets. 2006-7

[9]
Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.

Biochim Biophys Acta. 2016-12

[10]
CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.

Mol Cancer. 2022-4-22

引用本文的文献

[1]
Carvedilol sensitizes paclitaxel-resistant gastric cancer AGS cells to paclitaxel: influences on apoptotic regulators, Notch, PI3K/AKT, ERK1/2 signaling pathways, and miR-34a expression.

Med Oncol. 2025-7-30

[2]
ML210 Antagonizes ABCB1- Not ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.

Biomedicines. 2025-5-20

[3]
CDK5-triggered G6PD phosphorylation at threonine 91 facilitating redox homeostasis reveals a vulnerability in breast cancer.

Acta Pharm Sin B. 2025-3

[4]
An insight into the antitumor therapeutic potential of indole-(fused) pyri(mi)dine hybrids.

Future Med Chem. 2025-5

[5]
Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis.

Mol Cancer. 2025-4-19

[6]
Natural polymer derivative-based pH-responsive nanoformulations with entrapped diketo-tautomers of 5-fluorouracil for enhanced cancer therapy.

ADMET DMPK. 2025-1-3

[7]
Development of indole hybrids for potential lung cancer treatment - part II.

Future Med Chem. 2025-4

[8]
Development of indole hybrids for potential lung cancer treatment-part I: nitrogen-containing six-membered aromatic heterocycles.

Future Med Chem. 2025-4

[9]
Editorial: Molecular mechanisms and therapeutic targets of cancer metastasis and therapy resistance.

Front Oncol. 2025-3-5

[10]
AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer.

Acta Pharm Sin B. 2024-12

本文引用的文献

[1]
Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators.

Cancer Drug Resist. 2019-9-19

[2]
HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression.

Clin Transl Med. 2022-5

[3]
The Apoptotic Resistance of BRCA1-Deficient Ovarian Cancer Cells is Mediated by cAMP.

Front Cell Dev Biol. 2022-4-20

[4]
Co-treatment of Low Dose Pacritinib, a Phase III Jak2 Inhibitor, Greatly Increases Apoptosis of P-gp Over-expressing Cancer Cells With Multidrug Resistance.

Anticancer Res. 2022-5

[5]
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.

Eur J Med Chem. 2022-7-5

[6]
Down-regulation of ABCB1 by collateral sensitivity drugs reverses multidrug resistance and up-regulates enolase I.

J Biochem. 2022-6-28

[7]
CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.

Mol Cancer. 2022-4-22

[8]
Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy.

J Control Release. 2022-6

[9]
Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells.

Front Pharmacol. 2022-4-1

[10]
EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.

Cell Death Dis. 2022-4-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索